查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995468

標靶藥物遞送系統市場：依藥物類型、給藥途徑、技術、治療應用、最終用戶和銷售管道分類－2026年至2032年全球市場預測

Targeted Drug Delivery System Market by Drug Type, Delivery Route, Technology, Therapeutic Application, End User, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，標靶藥物輸送系統市場價值將達到 130.4 億美元，到 2026 年將成長至 139.2 億美元，到 2032 年將達到 213.2 億美元，複合年成長率為 7.26%。

主要市場統計數據
基準年 2025 130.4億美元
預計年份：2026年 139.2億美元
預測年份 2032 213.2億美元
複合年成長率 (%) 7.26%

這是一本關於標靶藥物遞送的權威指南，概述了臨床重點、轉化研究挑戰以及對開發人員和相關人員的戰略意義。

標靶藥物遞送技術透過實現精準定位、可控釋放和提高治療指數，正在變革臨床實踐、產品開發和患者療效。本文概述了遞送方式創新、先進載體整合以及生物製藥與新型化學品融合的戰略重要性，為理解臨床應用和商業性化優先排序背後的促進因素奠定了基礎。

載體的科學突破、與生物製藥的整合以及不斷變化的監管和支付方期望如何從根本上重塑標靶遞送的發展。

標靶藥物遞送領域正經歷著一場變革，其驅動力包括深刻的生物學見解、平台工程的突破以及監管機構對安全性和真實世界數據的日益重視。載體設計的進步，包括精確的奈米顆粒表面化學和配體驅動的靶向，正在提高治療指數，並為以往難以成藥的靶點開闢新的可能性。同時，遞送技術與基因和細胞療法的融合正在催生混合療法，拓展治療應用範圍，這也對新的生產和品管系統提出了更高的要求。

對近期美國關稅變化如何影響開發商的供應鏈多元化、區域製造地決策和採購彈性進行實際分析。

美國近期關稅政策的變化為定向輸送系統開發商和製造商在供應鏈規劃、零件採購和成本結構方面帶來了新的考量。依賴國際採購的特殊添加劑、先進聚合物或精密製造設備的製造商正面臨日益複雜的採購流程。這些變化促使各企業重新評估其供應商多元化策略，考慮區域化生產，並評估關鍵上游工程投入品的垂直整合，以降低貿易政策波動帶來的風險。

透過提供基於細分的詳細觀點，將治療領域、給藥途徑、平台技術、藥物模式、終端用戶環境和銷售管道聯繫起來，我們確定了發展中的關鍵轉折點。

要深入了解市場細分，需要整合治療領域、給藥途徑、技術平台、藥物模式、終端用戶趨勢和銷售管道，從而形成對市場採納促進因素的多維度觀點。基於治療應用，該領域涵蓋自體免疫疾病、心血管疾病、中樞神經系統疾病、腫瘤和整形外科適應症，其中腫瘤研究進一步細分為乳癌、結直腸癌和肺癌，每種癌症都需要獨特的靶向策略和安全性特徵。給藥途徑細分包括吸入、眼內、靜脈注射、局部注射、口服和經皮給藥，其中吸入途徑本身又可進一步分為乾粉吸入器、定量吸入器和霧化器，這些因素決定了製劑和裝置的要求。

美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何對藥物給藥技術的監管方法、生產策略和臨床應用產生不同的影響？

區域趨勢影響技術採納、監管策略和供應鏈結構，導致各區域臨床重點、報銷模式和生產生態系統各不相同。在美洲，強大的臨床試驗網路、完善的報銷框架和以規模化為導向的生產能力，為快速轉化研究和商業化策略提供了支持，這些策略優先考慮衛生經濟學證據。在該地區運作的申辦者通常優先考慮與複雜的醫療服務提供者系統互通性，以及順利納入處方集和臨床指南的流程。

透過平台擴充性、品質系統和主導商業化，企業採取策略行動和合作模式，在目標交付領域創造競爭優勢。

精準醫療領域的主要企業正透過平台擴充性、合規性和為支付方和醫療服務提供者創造綜合價值等關鍵領域實現差異化競爭。與技術開發人員和大型製造商建立策略合作夥伴關係，加速了商業化進程；而與臨床網路的夥伴關係有助於設計以真實世界療效為導向的可操作性臨床試驗。投資於模組化製造技術和完善品質系統的公司，透過縮短技術轉移週期和簡化監管檢查流程，正在建立競爭優勢。

為減少轉化障礙、保障供應鏈、透過主導開發和策略夥伴關係加速臨床部署，提出綜合可行的建議。

產業領導者應優先採取一系列切實可行的措施，以減少轉化阻力、確保供應連續性並加速臨床應用。首先，透過將以療效為導向的終點指標納入早期臨床通訊協定，並使這些終點指標與支付方的證據預期保持一致，從而簡化報銷談判。其次，透過關鍵材料來源多元化以及評估近岸外包和雙重採購方案，降低貿易政策和物流中斷帶來的風險。第三，投資於模組化、符合GMP規範的生產技術，以支援快速規模化生產並簡化跨區域技術轉移。

我們透明嚴謹的調查方法，結合了對專家的直接訪談、對第二手資料的全面整合以及交叉檢驗，從而得出可靠且可操作的見解。

本研究途徑整合了定性和定量方法，建構了一個經過驗證且三角驗證的證據基礎，以檢驗。主要研究包括對製藥科學家、臨床研究人員、監管專家、生產經理和採購負責人進行結構化訪談，以獲取關於技術性能、應用障礙和營運限制的第一手觀點。次要研究整合了同行評審文獻、監管指導文件、臨床試驗註冊信息和企業資訊披露信息，以闡明技術趨勢和監管預期。

簡明扼要地整合了策略挑戰，展示了綜合開發、有韌性的供應鏈和證據一致性如何決定跨治療領域的轉化研究的成功。

綜上所述，這些研究結果表明，標靶藥物遞送技術正處於一個轉折點，科學創新、監管進步和切實可行的商業化策略在此交匯融合，釋放出在多種適應症領域的巨大治療潛力。成功不僅取決於技術優勢，還取決於建立循證框架、確保穩健的供應鏈以及使產品特性與臨床工作流程相匹配的能力。那些採用整合式開發計劃、投資建設高度靈活的生產設施並及早與監管機構和支付方等相關人員進行溝通的企業，將能夠開闢一條永續的推廣之路。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按藥物類型分類的標靶藥物遞送系統市場

  • 生物製藥
  • 核酸
  • 胜肽
  • 低分子化合物

第9章 依給藥途徑分類的標靶藥物遞送系統市場

  • 吸入
    • 乾粉吸入器
    • 定量吸入器
    • 噴霧器
  • 眼
  • 靜脈
  • 局部注射
  • 口服
  • 經皮

第10章 標靶藥物遞送系統市場：依技術分類

  • 抗體藥物複合體
  • 樹狀聚合物
  • 脂質體
  • 微球
  • 奈米顆粒

第11章 按治療應用分類的標靶藥物遞送系統市場

  • 自體免疫
  • 心血管系統
  • 中樞神經系統
  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 肺癌
  • 整形外科

第12章 標靶藥物遞送系統市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
  • 研究機構

第13章 標靶藥物遞送系統市場：依銷售管道分類

  • 直接競標
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 標靶藥物遞送系統市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 標靶藥物遞送系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 標靶藥物遞送系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國標靶藥物傳輸系統市場

第18章：中國標靶藥物遞送系統市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4103B31E0A98

The Targeted Drug Delivery System Market was valued at USD 13.04 billion in 2025 and is projected to grow to USD 13.92 billion in 2026, with a CAGR of 7.26%, reaching USD 21.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.04 billion
Estimated Year [2026] USD 13.92 billion
Forecast Year [2032] USD 21.32 billion
CAGR (%) 7.26%

An authoritative orientation to targeted drug delivery that frames clinical priorities, translational hurdles, and strategic implications for developers and healthcare stakeholders

Targeted drug delivery technologies are reshaping clinical practice, product development, and patient outcomes by enabling precise localization, controlled release, and improved therapeutic indices. This introduction frames the strategic importance of delivery modality innovation, integration of advanced carriers, and the intersection of biologics and novel chemistries, setting a foundation for understanding the drivers behind clinical adoption and commercial prioritization.

Clinical stakeholders increasingly prioritize delivery approaches that reduce systemic exposure, minimize dosing frequency, and enhance patient adherence, while developers focus on platform scalability and regulatory tractability. Against this backdrop, the report synthesizes technological advances, regulatory dynamics, and translational barriers, creating a coherent narrative that informs research investment decisions and portfolio alignment for organizations navigating the evolving targeted delivery landscape.

How scientific breakthroughs in carriers, convergence with biotherapeutics, and evolving regulatory and payer expectations are fundamentally reconfiguring targeted delivery development

The targeted drug delivery landscape is undergoing transformative shifts driven by deeper biological insights, platform engineering breakthroughs, and evolving regulatory emphasis on safety and real-world evidence. Advances in carrier design, including precision nanoparticle surface chemistry and ligand-directed targeting, are enabling higher therapeutic indices and opening new windows for previously undruggable targets. Concurrently, the convergence of delivery technologies with gene and cell modalities is creating hybrid approaches that expand therapeutic reach and demand novel manufacturing and quality frameworks.

Parallel shifts in payer and provider expectations emphasize value demonstrated through improved outcomes and healthcare utilization metrics, prompting developers to build more robust evidence packages and to pursue pragmatic clinical endpoints. The rapid iteration of inhalation, ocular, and localized injection strategies for site-specific therapies reflects an industry eager to balance efficacy gains with patient-centric delivery. Taken together, these forces are accelerating translational pathways while elevating the importance of cross-disciplinary partnerships between formulation scientists, clinicians, and regulatory specialists.

Practical analysis of how recent United States tariff changes compel supply chain diversification, regional manufacturing decisions, and procurement resilience for developers

Recent tariff developments in the United States have injected new considerations into supply chain planning, component sourcing, and cost structures for developers and manufacturers of targeted delivery systems. Manufacturers that rely on specialized excipients, advanced polymers, or precision manufacturing equipment sourced internationally face increased procurement complexity. These dynamics are prompting organizations to reassess supplier diversification strategies, consider regionalized manufacturing, and evaluate vertical integration for critical upstream inputs to mitigate exposure to trade policy volatility.

The tariff environment also influences decisions on clinical and commercial manufacturing footprints as sponsors weigh the trade-offs between cost, lead time, and regulatory consistency. For many organizations, the cumulative effect of tariffs has catalyzed a re-evaluation of nearshoring and dual-sourcing models to preserve program timelines and maintain predictable product quality. Companies that proactively adapt contracting practices, incorporate tariff sensitivity into procurement analytics, and engage in collaborative supply chain transparency are better positioned to maintain continuity amid policy shifts.

Deep segmentation-driven perspective that interlinks therapeutic areas, delivery routes, platform technologies, drug modalities, end-user settings, and sales channels to reveal critical development inflection points

Segmentation insight requires integrating therapeutic focus, delivery route, technology platform, drug modality, end-user dynamics, and sales pathways to form a multidimensional view of adoption drivers. Based on therapeutic application, the field encompasses autoimmune, cardiovascular, central nervous system, oncology, and orthopedic indications, with oncology research further differentiated into breast, colorectal, and lung cancers, each demanding distinct targeting strategies and safety profiles. Delivery route segmentation captures inhalation, intraocular, intravenous, local injection, oral, and transdermal approaches, and recognizes that inhalation itself breaks down into dry powder inhaler, metered dose inhaler, and nebulizer formats that shape formulation and device requirements.

Technology segmentation highlights the heterogeneity of platform engineering, spanning antibody drug conjugates, dendrimers, liposomes, microspheres, and nanoparticles, each presenting unique pharmacokinetic and regulatory considerations. Drug type distinctions among biologics, nucleic acids, peptides, and small molecules determine stability, encapsulation needs, and analytical controls, while end users such as ambulatory surgical centers, clinics, hospitals, and research institutes influence deployment logistics and training requirements. Finally, sales channel segmentation that includes direct tender, hospital pharmacy, online pharmacy, and retail pharmacy affects commercialization planning, reimbursement interactions, and post-market surveillance strategies. When these dimensions are cross-referenced, they reveal high-value combinations and critical development inflection points where scientific choices intersect with clinical pathways and commercial access.

How Americas, Europe Middle East & Africa, and Asia-Pacific regional dynamics distinctly influence regulatory approaches, manufacturing strategies, and clinical adoption of delivery technologies

Regional dynamics shape technology adoption, regulatory strategy, and supply chain architecture, with each region presenting distinct clinical priorities, reimbursement models, and manufacturing ecosystems. In the Americas, robust clinical trial networks, established reimbursement frameworks, and scale-oriented manufacturing capacity favor rapid translational efforts and commercialization strategies that emphasize health-economic evidence. Sponsors operating in this region frequently prioritize interoperability with complex provider systems and navigable pathways for inclusion in formularies and clinical guidelines.

Europe, the Middle East & Africa present a heterogeneous regulatory and payer landscape where regional harmonization efforts coexist with country-specific requirements, creating both collaborative opportunities through centralized assessment bodies and localized access challenges. In these territories, value demonstration and real-world data are pivotal to securing adoption across diverse healthcare systems. Asia-Pacific combines rapid demand growth with evolving regulatory sophistication, strong contract manufacturing presence, and a growing emphasis on domestic innovation. Companies targeting this region often balance expedited commercialization with the need to adapt to local clinical preferences and manufacturing partnerships, optimizing product profiles to meet variable delivery route preferences and patient adherence considerations.

Strategic company behaviors and collaborative models that drive competitive advantage through platform scalability, quality systems, and evidence-led commercialization in targeted delivery

Leading companies in the targeted delivery space are differentiating through focus areas that include platform scalability, regulatory alignment, and integrated value generation for payers and providers. Strategic collaborations between technology developers and large-scale manufacturers are accelerating commercial readiness, while partnerships with clinical networks enable the design of pragmatic trials that emphasize real-world outcomes. Firms investing in modular manufacturing technologies and robust quality systems are creating competitive advantages by shortening tech transfer timelines and easing regulatory inspections.

Intellectual property strategies remain central, with forward-looking organizations protecting core formulation approaches and device interfaces while pursuing freedom-to-operate for combination products. Business models vary from platform license plays to fully integrated product development and commercialization, and successful players combine deep translational expertise with disciplined external engagement-policy stakeholders, payers, and patient advocacy groups-to align product value with clinical unmet needs. Companies that pair technical excellence with transparent evidence generation and adaptive commercialization channels are best positioned to translate scientific promise into clinical impact.

Consolidated and pragmatic recommendations for reducing translational barriers, securing supply chains, and accelerating clinical adoption through evidence-driven development and strategic partnerships

Industry leaders should prioritize a set of actionable initiatives that reduce translational friction, protect supply continuity, and accelerate clinical adoption. First, embed delivery-focused endpoints into early clinical protocols and align those endpoints with payer evidence expectations to streamline reimbursement conversations. Second, diversify sourcing for critical materials and evaluate nearshoring or dual-sourcing options to reduce exposure to trade policy and logistics disruptions. Third, invest in modular, GMP-compliant manufacturing technologies that support rapid scale-up and simplify tech transfer across geographies.

Additionally, cultivate interdisciplinary teams that bring formulation scientists, clinicians, health economists, and regulatory experts into continuous collaboration to anticipate approval hurdles and optimize product profiles. Strengthen IP strategies around combination products and device interfaces while exploring strategic licensing to broaden application reach. Finally, pursue targeted partnerships with healthcare providers and patient groups to design adoption-friendly delivery formats and patient support services that improve real-world outcomes and clinician acceptance. These actions create a pragmatic pathway from laboratory innovation to durable clinical implementation.

Transparent and rigorous research methodology combining primary expert interviews, comprehensive secondary synthesis, and cross-validation to support robust and actionable insights

The research approach integrates qualitative and quantitative methods to build a validated, triangulated evidence base for analysis. Primary research included structured interviews with formulation scientists, clinical investigators, regulatory experts, manufacturing leads, and procurement officers to capture firsthand perspectives on technology performance, adoption barriers, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to contextualize technological trends and regulatory expectations.

Data synthesis applied cross-validation techniques to reconcile disparate information sources, and scenario analysis was used to stress-test supply chain and regulatory contingencies. Where gaps were identified, targeted follow-up interviews and document requests addressed uncertainties and enhanced confidence in the conclusions. The methodology emphasizes transparency about data provenance and acknowledged limitations, advising readers on the interpretive boundaries of the findings and on the importance of complementing this analysis with program-specific due diligence.

Concise synthesis of strategic imperatives showing how integrated development, resilient supply chains, and evidence alignment will determine translational success across therapeutic areas

The aggregate insights highlight that targeted drug delivery is at an inflection point where scientific innovation, regulatory evolution, and pragmatic commercialization strategies converge to unlock therapeutic potential across multiple indications. Success hinges not only on technological superiority but also on the ability to design evidence frameworks, secure resilient supply chains, and align product characteristics with clinical workflows. Organizations that adopt integrated development plans, invest in adaptable manufacturing, and engage early with regulatory and payer stakeholders will create durable pathways to adoption.

Looking forward, stakeholders should expect incremental advances in carrier engineering and device integration to continue expanding the therapeutic boundaries, particularly where delivery enables safer administration of potent therapeutics or targeted modulation of disease biology. The combination of strategic partnerships, disciplined execution, and a relentless focus on real-world impact will determine which innovations translate into measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Drug Delivery System Market, by Drug Type

  • 8.1. Biologics
  • 8.2. Nucleic Acids
  • 8.3. Peptides
  • 8.4. Small Molecule

9. Targeted Drug Delivery System Market, by Delivery Route

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhaler
    • 9.1.2. Metered Dose Inhaler
    • 9.1.3. Nebulizer
  • 9.2. Intraocular
  • 9.3. Intravenous
  • 9.4. Local Injection
  • 9.5. Oral
  • 9.6. Transdermal

10. Targeted Drug Delivery System Market, by Technology

  • 10.1. Antibody Drug Conjugates
  • 10.2. Dendrimers
  • 10.3. Liposomes
  • 10.4. Microspheres
  • 10.5. Nanoparticles

11. Targeted Drug Delivery System Market, by Therapeutic Application

  • 11.1. Autoimmune
  • 11.2. Cardiovascular
  • 11.3. Central Nervous System
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Lung Cancer
  • 11.5. Orthopedic

12. Targeted Drug Delivery System Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Targeted Drug Delivery System Market, by Sales Channel

  • 13.1. Direct Tender
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. Targeted Drug Delivery System Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Targeted Drug Delivery System Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Targeted Drug Delivery System Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Targeted Drug Delivery System Market

18. China Targeted Drug Delivery System Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. F. Hoffmann-La Roche Ltd
  • 19.8. GSK plc
  • 19.9. Johnson & Johnson
  • 19.10. Merck & Co., Inc.
  • 19.11. Novartis AG
  • 19.12. Pfizer Inc.
  • 19.13. Sanofi S.A.
  • 19.14. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)